Loading...
Market
How many units of the new FDA-approved nasal spray will be sold by the end of 2024?
3
Resolution / Starting Odds
Less than 1 million units • 25%
1 to 2 million units • 25%
2 to 3 million units • 25%
More than 3 million units • 25%
Pharmaceutical sales data from publicly available financial reports or press releases
Story
FDA Approves Nasal Spray for Severe Allergies
Aug 21, 2024, 02:20 AM
The US Food and Drug Administration (FDA) has approved a new nasal spray device for administering epinephrine, the active ingredient in EpiPens, to treat severe allergies. This innovative approach offers an alternative to the traditional needle-based method, providing a potentially life-saving solution for patients who experience severe allergic reactions but are hesitant to use EpiPens. The nasal spray is designed to address both mild and severe allergies, marking a significant advancement in allergy treatment.
View original story
Similar markets
Yes • 50%
No • 50%
1 to 2 million • 25%
Less than 1 million • 25%
2 to 3 million • 25%
More than 3 million • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 100,000 units • 25%
100,000 to 500,000 units • 25%
500,000 to 1 million units • 25%
More than 1 million units • 25%
Less than 500,000 units • 25%
500,000 to 1 million units • 25%
1 million to 2 million units • 25%
More than 2 million units • 25%
Less than 500,000 • 25%
500,000 to 1 million • 25%
1 million to 2 million • 25%
More than 2 million • 25%
COVID-19 prevention • 25%
Influenza prevention • 25%
Bacterial infection prevention • 25%
General respiratory health • 25%
